Fri, January 21, 2011
Thu, January 20, 2011
Wed, January 19, 2011
Tue, January 18, 2011
Mon, January 17, 2011
Fri, January 14, 2011
[ Fri, Jan 14th 2011 ] - Market Wire
ICON Acquires Oxford Outcomes
Thu, January 13, 2011
Wed, January 12, 2011
Tue, January 11, 2011
Mon, January 10, 2011
[ Mon, Jan 10th 2011 ] - Market Wire
Teleflex Acquires VasoNova Inc.
[ Mon, Jan 10th 2011 ] - Market Wire
30 A.M. ET
Sun, January 9, 2011
Fri, January 7, 2011
Thu, January 6, 2011
Wed, January 5, 2011
Tue, January 4, 2011
Mon, January 3, 2011
Fri, December 31, 2010
Thu, December 30, 2010
Wed, December 29, 2010
Tue, December 28, 2010
Mon, December 27, 2010
Fri, December 24, 2010
Thu, December 23, 2010
Wed, December 22, 2010
Tue, December 21, 2010
Mon, December 20, 2010

Ironwood Pharmaceuticals Announces Upcoming Presentation at J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. ntation-at-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on Thursday, January 6th 2011 at 14:05 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ Ironwood Pharmaceuticals, Inc. ] (NASDAQ: IRWD) will present at the 29th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2011 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time at The Westin St. Francis in San Francisco. The presentation will be followed by a question and answer session that will begin at approximately 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time.

A live webcast of both the presentation and the question and answer session will be accessible through the Investors section of Ironwooda™s website at [ www.ironwoodpharma.com ]. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of each webcast will be available on Ironwooda™s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwooda™s GCaC agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBSaC) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit [ www.ironwoodpharma.com ].


Publication Contributing Sources